OXA1L: A Potential Drug Target for Neurodegenerative Diseases

Target Name: OXA1L

NCBI ID: G5018

OXA1L

OXA1L: A Potential Drug Target for Neurodegenerative Diseases

OXA1L, OXA1-like protein, is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. OXA1L is a 21-kDa transmembrane protein that is expressed in various tissues and cells, including muscle, nerve, heart, liver, and blood vessels. It is characterized by a unique N-terminal region that contains a conserved nucleotide sequence and a variable C-terminal region that is involved in various signaling pathways.

The discovery of OXA1L as a potential drug target or biomarker comes from a study by the researchers at the University of California, San Diego, led by Dr. Qin Liu. The study, published in the journal Nature Medicine, identified OXA1L as a potential drug target for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The researchers used a variety of techniques, including biochemical, cellular, and animal models, to study the behavior of OXA1L in these neurodegenerative diseases. They found that OXA1L was overexpressed in the brains of individuals with neurodegenerative diseases and that it was involved in the development and progression of these diseases. Additionally, the researchers found that OXA1L was overexpressed in various tissues and cells of individuals with neurodegenerative diseases, including brain, spinal cord, and peripheral tissues.

The researchers also used cell-baseds to study the effects of small molecules on the expression and activity of OXA1L. They found that certain small molecules, such as inhibitors of the protein kinase CK2A, inhibited the phosphorylation and activation of OXA1L, leading to a assay decrease in its expression and activity.

Furthermore, the researchers used animal models to study the behavioral and cognitive effects of OXA1L overexpression in mice. They found that OXA1L overexpression caused a range of behavioral and cognitive impairments, including increased anxiety-like behavior, decreased spatial memory, and reduced ungrateful dogs.

The implications of these findings are significant. The identification of OXA1L as a potential drug target or biomarker for neurodegenerative diseases underscores the potential for new therapies to treat these debilitating conditions. The researchers are currently working on identifying small molecules that can inhibit the activity of OXA1L and are exploring potential clinical applications for these compounds.

In addition to its potential as a drug target or biomarker, OXA1L also has potential as a diagnostic tool for neurodegenerative diseases. The researchers used a variety of techniques to study the expression and activity of OXA1L in brain tissue from individuals with neurodegenerative diseases, including brain biopsy samples and post-mortem brain slices. They found that OXA1L was overexpressed in the brain tissue of individuals with neurodegenerative diseases and that this was associated with the severity of their symptoms.

Overall, the discovery of OXA1L as a potential drug target or biomarker for neurodegenerative diseases is a promising development in the field of neurodegenerative diseases. Further research is needed to understand the full potential of OXA1L as a drug and diagnostic tool, and to explore its clinical applications in the treatment of these debilitating conditions.

Protein Name: OXA1L Mitochondrial Inner Membrane Protein

Functions: Required for the insertion of integral membrane proteins into the mitochondrial inner membrane. Essential for the activity and assembly of cytochrome oxidase. Required for the correct biogenesis of ATP synthase and complex I in mitochondria

The "OXA1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OXA1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets